Ferry Ossendorp

Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.

Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors.

CD4 T cells and their role in antitumor immune responses.

Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli.

Differential influence on cytotoxic T lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28.

Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis.

Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells.

Reorganization of multivesicular bodies regulates MHC class II antigen presentation by dendritic cells.

Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo.

Identification of a novel HLA-B60-restricted T cell epitope of the minor histocompatibility antigen HA-1 locus.

Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells.

Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes.

The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein.

Prolongation of skin graft survival by modulation of the alloimmune response with alternatively activated dendritic cells.

New chelation strategy allows for quick and clean 99mTc-labeling of synthetic peptides.

Gamma irradiation or CD4+-T-cell depletion causes reactivation of latent Salmonella enterica serovar Typhimurium infection in C3H/HeN mice.

Differential expression regulation of the alpha and beta subunits of the PA28 proteasome activator in mature dendritic cells.

Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes.

Murine Fc receptors for IgG are redundant in facilitating presentation of immune complex derived antigen to CD8+ T cells in vivo.

Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants.

Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine.

Dendritic cells, but not macrophages or B cells, activate major histocompatibility complex class II-restricted CD4+ T cells upon immune-complex uptake in vivo.

A novel role of complement factor C1q in augmenting the presentation of antigen captured in immune complexes to CD8+ T lymphocytes.

Steric hindrance and fast dissociation explain the lack of immunogenicity of the minor histocompatibility HA-1Arg Null allele.

Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity.

DC-induced CD8(+) T-cell response is inhibited by MHC class II-dependent DX5(+)CD4(+) Treg.

Effective CD8(+) T cell priming and tumor protection by enterotoxin B subunit-conjugated peptides targeted to dendritic cells.

Activity-based profiling reveals reactivity of the murine thymoproteasome-specific subunit beta5t.

Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes.

Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors.

Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers.

The inhibiting Fc receptor for IgG, FcγRIIB, is a modifier of autoimmune susceptibility.

Circulating specific antibodies enhance systemic cross-priming by delivery of complexed antigen to dendritic cells in vivo.

Fcγ receptor IIb strongly regulates Fcγ receptor-facilitated T cell activation by dendritic cells.

Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors.

Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles.

Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer.

Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects.

Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation.

New role of signal peptide peptidase to liberate C-terminal peptides for MHC class I presentation.

Local immunomodulation for cancer therapy: Providing treatment where needed.

Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer.

IgG-mediated anaphylaxis to a synthetic long peptide vaccine containing a B cell epitope can be avoided by slow-release formulation.

Ovalbumin-coated pH-sensitive microneedle arrays effectively induce ovalbumin-specific antibody and T-cell responses in mice.

Dominant contribution of the proteasome and metalloproteinases to TAP-independent MHC-I peptide repertoire.

Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study.

Enhanced cross-presentation and improved CD8+ T cell responses after mannosylation of synthetic long peptides in mice.

FcRγ-chain ITAM signaling is critically required for cross-presentation of soluble antibody-antigen complexes by dendritic cells.

Near-infrared labeled, ovalbumin loaded polymeric nanoparticles based on a hydrophilic polyester as model vaccine: In vivo tracking and evaluation of antigen-specific CD8(+) T cell immune response.

CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.

Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death.

Two in one: improving synthetic long peptide vaccines by combining antigen and adjuvant in one molecule.

Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.

The translocon protein Sec61 mediates antigen transport from endosomes in the cytosol for cross-presentation to CD8(+) T cells.

Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer.

Therapeutic cancer vaccines.

The viral context instructs the redundancy of costimulatory pathways in driving CD8(+) T cell expansion.

Combination of Photodynamic Therapy and Specific Immunotherapy Efficiently Eradicates Established Tumors.

TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors.

Vaccines for established cancer: overcoming the challenges posed by immune evasion.

Glycan modification of antigen alters its intracellular routing in dendritic cells, promoting priming of T cells.

TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients.

The Optimization of Bioorthogonal Epitope Ligation within MHC-I Complexes.

Strong in vivo antitumor responses induced by an antigen immobilized in nanogels via reducible bonds.

Self-Assembling Peptide Epitopes as Novel Platform for Anticancer Vaccination.

C1q-Dependent Dendritic Cell Cross-Presentation of In Vivo-Formed Antigen-Antibody Complexes.

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy.

CD4 T Cell and NK Cell Interplay Key to Regression of MHC Class I Tumors upon TLR7/8 Agonist Therapy.

PD-L1 immune suppression in cancer: Tumor cells or host cells?

Photodynamic-Immune Checkpoint Therapy Eradicates Local and Distant Tumors by CD8 T Cells.

Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses.

A Restricted Role for FcγR in the Regulation of Adaptive Immunity.

Sustained cross-presentation capacity of murine splenic dendritic cell subsets in vivo.

Chemical Control over T-Cell Activation in Vivo Using Deprotection of trans-Cyclooctene-Modified Epitopes.

Formation of Immune Complexes with a Tetanus-Derived B Cell Epitope Boosts Human T Cell Responses to Covalently Linked Peptides in an Ex Vivo Blood Loop System.

Approaches to Improve Chemically Defined Synthetic Peptide Vaccines.

Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences.

FcγRI expression on macrophages is required for antibody-mediated tumor protection by cytomegalovirus-based vaccines.

FcγR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model.

High FcγR Expression on Intratumoral Macrophages Enhances Tumor-Targeting Antibody Therapy.

: A workflow for visual and quantitative analysis of flow and mass cytometry data to discover immune signatures and correlations.

Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.

Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication.

A Dual-Color Bioluminescence Reporter Mouse for Simultaneous Imaging of T Cell Localization and Function.

Dual Synthetic Peptide Conjugate Vaccine Simultaneously Triggers TLR2 and NOD2 and Activates Human Dendritic Cells.

Peptides conjugated to 2-alkoxy-8-oxo-adenine as potential synthetic vaccines triggering TLR7.

PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors.

Effective chemoimmunotherapy by co-delivery of doxorubicin and immune adjuvants in biodegradable nanoparticles.

A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control.

Cationic synthetic long peptides-loaded nanogels: An efficient therapeutic vaccine formulation for induction of T-cell responses.